Concepedia

Author

Duncan B. McLaren

Western General HospitalORCID

Also Known As

D MCLAREN, D McLaren, D. B. McLaren, D. McLaren, D.B. McLaren, D.B. Mclaren, DB McLaren, Duncan B. McLaren, Duncan B McLaren, Duncan B. McLaren

145

Publications

5.3K

Citations

27

H-Index

80

Concepts

All Affiliations

Western General HospitalUniversity of EdinburghRoyal Marsden NHS Foundation TrustEdinburgh Cancer ResearchBeatson West of Scotland Cancer Centre
DB

About

Duncan B. McLaren is an author at Western General Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

21

842

2

Health Sciences

5

5

130

3

Engineering

3

3

64

4

Anatomy

3

3

160

5

Public Health

1

1

41

Duncan B. McLaren

×

45

Publications

4.9K

Citations

26

H-Index

YearCitations

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke,

The Lancet

2015

1.9K

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquı́n Mateo, Núria Porta, Diletta Bianchini,

The Lancet Oncology

2019

632

Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

Nicholas D. James, Melissa Spears, Noel W. Clarke,

European Urology

2014

431

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Matthew R. Sydes, Melissa Spears, Malcolm D. Mason,

Annals of Oncology

2018

240

Clinical and patient‐reported outcomes of <scp>SPARE</scp> – a randomised feasibility study of selective bladder preservation versus radical cystectomy

Robert Huddart, Alison Birtle, Lauren Maynard,

British Journal of Urology

2017

151

Watchful waiting or watchful progression?

Duncan B. McLaren, Michael McKenzie, Graeme Duncan,

Cancer

1998

98

Watchful Waiting or Watchful Progression? Prostate Specific Antigen Doubling Times and Clinical Behavior in Patients With Early Untreated Prostate Carcinoma

Duncan B. McLaren, Michael McKenzie, Gillian Duncan,

The Journal of Urology

1998

94

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both

Nicholas D. James, Sarah Pirrie, Ann Pope,

JAMA Oncology

2016

87

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard, Laura Murphy, Noel W. Clarke,

The Lancet Oncology

2023

85

Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy

D. Storey, Duncan B. McLaren, M.A. Atkinson,

Annals of Oncology

2011

84

Page 1